{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-25-000043","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.965785+00:00","generated_at":"2026-05-24T21:14:27.742997+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nurix appoints former Merck CMO Roy Baynes to board of directors","bullets":["Appoints Roy D. Baynes (EVP & CMO of Eikon, former Merck CMO) as Class II director, effective March 11, 2025.","Received initial option for 50,000 shares vesting over 3 years; annual cash retainers of $50,000 (board) and $5,000 (committee).","Served on Medical Advisory Board since 2023; will advise on clinical development including NX-5948 for CLL.","No family relationships or material interests with directors/officers; standard indemnification agreement executed."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-25-000043","json":"https://secwatch.observer/filing/0001549595-25-000043.json","markdown":"https://secwatch.observer/filing/0001549595-25-000043.md","text":"https://secwatch.observer/filing/0001549595-25-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000043/0001549595-25-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000043/nrix-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:14:27.742997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}